Immatics stock gains 2.22 percent as analysts see upside

Published on 10/05/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immatics stock trades at USD 7.76 on October 5, 2026, after touching USD 7.40 on October 3. Eight analysts give a Moderate Buy consensus and USD 20.60 average target.

IMTX, NL0015285941, Illustration mit AI erstellt.

Immatics stock (ISIN NL0015285941) was trading at USD 7.76 on Nasdaq on October 5, 2026, up 2.22 percent from the previous close. The move follows a slide to a new 52-week low of USD 7.40 on October 3, keeping the clinical-stage biotechnology company close to the lower end of its USD 7.40 to USD 12.41 yearly range.

Analysts see a wider valuation gap

According to MarketBeat on October 3, 2026, eight analysts carried a Moderate Buy consensus, with six Buy ratings, one Hold rating and one Sell rating. The average 12-month price target was USD 20.60, which places the target 165.5 percent above the October 5 price of USD 7.76.

The consensus is set against a market capitalization of USD 1.0 billion on October 5, 2026. The valuation gap reflects the high-risk, development-stage profile of Immatics, whose pipeline centers on T-cell receptor therapies and T-cell engaging bispecific molecules for cancer treatment.

Q2 revenue rose but losses remained

MarketBeat reported that Immatics posted Q2 2026 earnings on August 18, 2026, with an EPS loss of USD 0.53 versus a consensus loss of USD 0.47. Revenue reached USD 10.44 million against the USD 12.42 million estimate, a shortfall of USD 1.98 million.

The latest quarterly figures leave clinical execution and funding capacity as the central operating variables. Immatics raised USD 150 million in an offering announced on August 25, 2026, while its SUPRAME Phase 3 program for anzu-cel remained a key development milestone in the company update carried by the market coverage.

Next results date is November 17

According to Yahoo Finance, Immatics is listed for a Q3 2026 earnings announcement on November 17, 2026. That date gives investors the next scheduled checkpoint for revenue, cash use and clinical progress.

Stock trades above its yearly low

Immatics stock was last at USD 7.76 on Nasdaq at 1:44 p.m. ET on October 5, 2026, with 279,490 shares traded. The price stood 4.9 percent above the 52-week low of USD 7.40 and 37.5 percent below the 52-week high of USD 12.41.